GT Biopharma (GTBP) Competitors

GT Biopharma (NASDAQ:GTBP) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Is GTBP or CYTH more profitable?

GT Biopharma has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Cyclo Therapeutics' return on equity of 0.00% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-257.47%	-131.09%
Cyclo Therapeutics	-2,847.19%	N/A	-307.16%

Does the media refer more to GTBP or CYTH?

In the previous week, Cyclo Therapeutics had 1 more articles in the media than GT Biopharma. MarketBeat recorded 4 mentions for Cyclo Therapeutics and 3 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.46 beat Cyclo Therapeutics' score of 0.72 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cyclo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor GTBP or CYTH?

GT Biopharma received 107 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 63.24% of users gave GT Biopharma an outperform vote.

Company	Underperform	Outperform
GT Biopharma	Outperform Votes 117 63.24%	Underperform Votes 68 36.76%
Cyclo Therapeutics	Outperform Votes 10 71.43%	Underperform Votes 4 28.57%

Which has more volatility & risk, GTBP or CYTH?

GT Biopharma has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500.

Do analysts recommend GTBP or CYTH?

GT Biopharma presently has a consensus price target of $11.00, suggesting a potential upside of 378.26%. Cyclo Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 31.83%. Given GT Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe GT Biopharma is more favorable than Cyclo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cyclo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do institutionals and insiders believe in GTBP or CYTH?

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are held by institutional investors. 10.9% of GT Biopharma shares are held by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, GTBP or CYTH?

GT Biopharma has higher earnings, but lower revenue than Cyclo Therapeutics. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$7.60M	-$7.00	-0.33
Cyclo Therapeutics	$870.73K	27.24	-$20.06M	-$0.90	-0.80

Summary

GT Biopharma beats Cyclo Therapeutics on 10 of the 17 factors compared between the two stocks.